Articles related to CLINICAL TRIALS

In a phase 3 study, iloperidone demonstrated a significant improvement in treating bipolar mania, marked by a reduction in the Young Mania Rating Scale (YMRS) scores.

In a recent phase II trial, patients with untreated metastatic pancreatic ductal adenocarcinoma receiving sequential nab-P/Gem-mFOLFOX experienced a median overall survival of 13.2 months, compared to 9.7 months in those receiving standard nab-P/Gem treatment, indicating a notable improvement in survival outcomes.

In the phase 3 GETUG-AFU 18 trial, high-dose radiotherapy (80 Gy) combined with long-term androgen deprivation therapy markedly improved 10-year progression-free and overall survival in high-risk prostate cancer patients, without additional toxicity.

In a recent study assessing chronic insomnia treatments in hemodialysis patients, no significant difference was observed between CBT-I, trazodone, and placebo in improving Insomnia Severity Index scores. This highlights a critical need for alternative therapeutic approaches in this unique patient population.

In a recent phase 3 trial, a low-dose chemotherapy regimen demonstrated noninferior efficacy to standard-dose regimens in pediatric AML patients, while significantly reducing non-hematologic toxicities, an important consideration in pediatric oncology.

In the CodeBreaK 100 study, a lower 240 mg dose of sotorasib demonstrated similar efficacy to the FDA-approved 960 mg dose in treating KRAS G12C–mutated NSCLC, with potentially fewer severe adverse events.